Dermatology Biotech Bambusa Dips 6.3% After $168.9 Million IPO

Bambusa Therapeutics Inc. shares slipped 6.3% in its trading debut after the early-stage biotech focused on dermatology and autoimmune diseases raised $168.9 million in a US initial public offering.